October 25, 2023 C-Path Announces Significant Expansion in Neonatal RWD Project Details of the expansion will be a highlight of the Institute’s Scientific Breakthrough Summit Oct. 26-27 in D.C. TUCSON, Ariz.,
October 3, 2023 C-Path Rare and Orphan Disease Conference Highlights Unprecedented Collaborations and Breakthroughs in Rare Disease Research TUCSON, Ariz., October 3, 2023 — The Critical Path Institute (C-Path) held its highly anticipated Rare and Orphan Disease Confer
September 18, 2023 C-Path and EATRIS Join Forces with New Collaboration Agreement AMSTERDAM and TUCSON, Ariz., September 18, 2023 — Critical Path Institute (C-Path) and EATRIS (the European Research Infrastruct
September 12, 2023 C-Path’s Rare Disease Clinical Outcome Assessment Consortium Launches Rare Disease COA Resource The Rare Disease COA Resource aims to simplify COA selection for use in rare disease drug development. TUCSON, Ariz., Septe
Postdoc Ruby Abrams Shares Professional Development Opportunities Provided by C-Path Critical Path Institute is dedicated to advancing careers in the medical development and regulatory science industries. We are hap
August 17, 2023 C-Path to Host a Scientific Breakthrough Summit Oct. 26-27 Addressing Unmet Regulatory Needs and Drug Development Opportunities through Collaborations in Type 1 Diabetes, Alpha-1 Antitrypsi
August 15, 2023 NORDs’ IAMRARE Registry Contributes Two New Datasets to C-Path’s RDCA-DAP, Boosting Rare Disease Research and Therapeutic Advancement TUCSON, Ariz., August 15, 2023 — Critical Path Institute (C-Path) announced today that the National Organization for Rare Disord
August 9, 2023 C-Path’s Duchenne Regulatory Science Consortium and Duchenne Data Foundation Announce Collaboration to Advance Solutions for Duchenne Muscular Dystrophy C-Path's Duchenne Regulatory Science Consortium (D-RSC) and the Duchenne Data Foundation (DDF) are excited to announce...
August 9, 2023 C-Path Welcomes Sanofi to its Type 1 Diabetes Consortium to Help Advance Drug Development The global immunology and diabetes leader will collaborate with C-Path’s T1DC to drive transformative change in type 1 diabe
July 19, 2023 The Foundation for Angelman Syndrome Therapeutics to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development TUCSON, Ariz., July 19, 2023 — Critical Path Institute (C-Path) announced today that the Foundation for Angelman Syndrome Therap